A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

← catalyst calendar

NCT07613307 · readout ≤ 285 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

130estimated

Sites

Countries

India, Saudi Arabia, South Africa +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Jul 2026

estimated

When the study began enrolling

Primary completion

May 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

May 2027

estimated

The whole study's end, after follow-up

First posted

2026-05-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Diabetes Mellitus, Type 2
Diabetes Melletus
Glucose Metabolism Disorders
Metabolic Disorders
Nutritional and Metabolic Diseases
Endocrine System Diseases
Feeding Behavior
Behavior
Fasting
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide Receptors
Receptors, G-Protein-Coupled
Receptors, Cell Surface
Membrane Proteins
Proteins
Receptors, Peptide

Intervention

Drug: Orforglipron — also filed as LY3502970

Primary outcome

what the primary-completion date above is the date OF

Change from Baseline in Hemoglobin A1C (HbA1c)

measured Baseline, up to 8 Weeks after Start of Ramadan

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed